DeutschNewstral
Article
New York Post on 2019-12-09 17:27
Shares of cancer-treatment company ArQule surge 100 percent on Merck acquisition
Related news
VTv Therapeutics shares surge 40 percentbizjournals.com- NAbercrombie shares surge nearly 20 percentnypost.com
Seattle biotech’s shares quadruple on news of buyout by MerckSeattle Times- BStantec shares jump on latest U.S. acquisition newsblogs.edmontonjournal.com
- Best Buy shares surge 14 percent on surprisingly strong salesNew York Post
- NSnap shares surge 20 percent on surprisingly strong resultsnypost.com
Alder shares surge on test results for migraine treatmentseattletimes.com- MMerck to buy cancer-treatment biotech Tilos Therapeutics for up to $773 millionmarketwatch.com
- MIncyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatmentmarketwatch.com
- MMerck shares surge anew on lung cancer advance, while Bristol-Myers stock plummetsmarketwatch.com
- MStaples shares surge on report of $6 billion acquisition by Sycamoremarketwatch.com
- EBay shares surge 12 percent after activist investor calls for breakupNew York Post
Shenzhen-listed shares of China's ZTE surge 10 percent in resumed tradeReuters- Fitbit shares surge more than 16 percent on signs of a turnaroundNew York Post
- Macy’s shares surge more than 20 percent on bright holiday outlookNew York Post
- BÖRSEN-TICKER-Krebsmittel-Test beflügelt Pharmafirma ArQuleReuters
- Apple shares surge nearly 7 percent after drop over coronavirus fearsNew York Post
- Tinder owner’s shares surge over 12 percent as online dating soars amid COVID-19 pandemicNew York Post
- MTherapix shares surge 30% premarket on news of positive trial of Tourette syndrome treatmentmarketwatch.com
- MPalatin shares surge 9% premarket after FDA accepts for review treatment for HSDDmarketwatch.com